ReviewKidney international. Supplement2010
Innate immunity and cardiac allograft rejection.
Review in Kidney international. Supplement, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Suppression of cardiac allograft vasculopathy by a macrophage efferocytosis receptor.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection.Transplantation direct · 2026Article
- Donor Age, Sex, and Cause of Death and Their Relationship to Heart Transplant Recipient Cardiac Death.Journal of clinical medicine · 2023Article
- Donor Macrophages Modulate Rejection After Heart Transplantation.Circulation · 2022Article
- Editorial: Advances in Heart Transplantation.Frontiers in immunology · 2022Article
- Failing Heart Transplants and Rejection-A Cellular Perspective.Journal of cardiovascular development and disease · 2021Review
- Tissue Dependent Role of PTX3 During Ischemia-Reperfusion Injury.Frontiers in immunology · 2019Review
- Natural Killer Cells Promote Kidney Graft Rejection Independently of Cyclosporine A Therapy.Frontiers in immunology · 2019Article
- Significant role for microRNA-21 affecting toll-like receptor pathway in primary graft dysfunction after human lung transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2017Article
- Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury.PloS one · 2017Article
- [Chronic rejection: Differences and similarities in various solid organ transplants].Der Internist · 2016Review
- Beyond cancer treatment - a review of total lymphoid irradiation for heart and lung transplant recipients.Journal of medical radiation sciences · 2014Review
- Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.Arteriosclerosis, thrombosis, and vascular biology · 2014Review
- Mannan-binding lectin in cardiovascular disease.BioMed research international · 2014Review
- NKG2D blockade attenuated cardiac allograft vasculopathy in a mouse model of cardiac transplantation.Clinical and experimental immunology · 2013Article
- An important role for autoimmunity in the immunopathogenesis of chronic allograft rejection.International journal of immunogenetics · 2012Review
- Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition γδT cells.Clinical and experimental immunology · 2012Article
- Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The development of immunosuppressive drugs to control adaptive immune responses has led to the success of heart transplantation as a therapy for end-stage heart failure. However, these agents are largely ineffective in suppressing components of the innate immune system. This distinction has gained clinical significance as mounting evidence now indicates that innate immune responses have important roles in the acute and chronic rejection of cardiac allografts including cardiac allograft vasculopathy (CAV). Whereas clinical interest in natural killer (NK) cells was once largely confined to the field of bone marrow transplantation, recent findings suggest that these cells can also participate in the acute rejection of cardiac allografts and in the development of CAV. Stimulation of Toll-like receptors (TLRs), another important component of innate immunity, by endogenous ligands released in response to ischemia/reperfusion is now known to cause an inflammatory milieu favorable to graft rejection. Finally, new data indicate that activation of complement is linked to acute rejection and CAV. In summary, the conventional wisdom that the innate immune system is of little importance in whole-organ transplantation is no longer tenable. The addition of strategies that target TLRs, NK cells, and complement will be necessary to prevent CAV completely and to eventually achieve long-term tolerance to cardiac allografts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.